Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes

Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan, Zhong Min Liu

Research output: Contribution to journalEditorial

4 Citations (Scopus)
Original languageEnglish
Pages (from-to)1267-1271
Number of pages5
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume12
Issue number11
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

Dipeptidyl-Peptidase IV Inhibitors
Medical problems
Glucose
Pharmaceutical Preparations
alogliptin
ZP10A peptide
Sitagliptin Phosphate
saxagliptin
Liraglutide
empagliflozin

Keywords

  • Alogliptin
  • dipeptidyl peptidase-4 inhibitors
  • empagliflozin
  • glucagon-like peptide-1 agonists
  • liraglutide
  • lixisenatide
  • saxagliptin
  • sitagliptin
  • sodium-glucose cotransporter 2 inhibitors
  • type 2 diabetes mellitus

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes. / Tomlinson, Brian; Hu, Miao; Zhang, Yuzhen; Chan, Paul; Liu, Zhong Min.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 12, No. 11, 01.11.2016, p. 1267-1271.

Research output: Contribution to journalEditorial

Tomlinson, Brian ; Hu, Miao ; Zhang, Yuzhen ; Chan, Paul ; Liu, Zhong Min. / Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes. In: Expert Opinion on Drug Metabolism and Toxicology. 2016 ; Vol. 12, No. 11. pp. 1267-1271.
@article{dc682884230844c1b502b7b1041d90ce,
title = "Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes",
keywords = "Alogliptin, dipeptidyl peptidase-4 inhibitors, empagliflozin, glucagon-like peptide-1 agonists, liraglutide, lixisenatide, saxagliptin, sitagliptin, sodium-glucose cotransporter 2 inhibitors, type 2 diabetes mellitus",
author = "Brian Tomlinson and Miao Hu and Yuzhen Zhang and Paul Chan and Liu, {Zhong Min}",
year = "2016",
month = "11",
day = "1",
doi = "10.1080/17425255.2016.1234608",
language = "English",
volume = "12",
pages = "1267--1271",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes

AU - Tomlinson, Brian

AU - Hu, Miao

AU - Zhang, Yuzhen

AU - Chan, Paul

AU - Liu, Zhong Min

PY - 2016/11/1

Y1 - 2016/11/1

KW - Alogliptin

KW - dipeptidyl peptidase-4 inhibitors

KW - empagliflozin

KW - glucagon-like peptide-1 agonists

KW - liraglutide

KW - lixisenatide

KW - saxagliptin

KW - sitagliptin

KW - sodium-glucose cotransporter 2 inhibitors

KW - type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=84988409411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988409411&partnerID=8YFLogxK

U2 - 10.1080/17425255.2016.1234608

DO - 10.1080/17425255.2016.1234608

M3 - Editorial

AN - SCOPUS:84988409411

VL - 12

SP - 1267

EP - 1271

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 11

ER -